Biomarkers for assessing breast cancer
US10962542B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 10, 2015 |
| Grant date | Mar 30, 2021 |
| Priority date | — |
| Expiry date | Jan 13, 2036 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10T436/24
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A metabolic biomarker set for use in assessing, screening, and/or diagnosing breast cancer in a mammalian subject includes at least (a) one amino acid selected from glutamine, glutamate and serine, and one lipid, or (b) glutamine and glutamate. Described further, is a metabolic biomarker set for prediction of therapeutic response to breast cancer neoadjuvant chemotherapy; a metabolic biomarker set for assessing biochemical reflection of breast cancer tumor activity; and a metabolic biomarker set for subclassification between intrinsic breast cancer tumor subtypes. Moreover, a method for assessing breast cancer is described, which includes obtaining a biological sample, preferably blood, from a mammalian subject and measuring in the biological sample the amount and/or ratios of metabolites. By employing the specific biomarkers and the method it becomes possible to more properly and reliably assess breast cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.